Results 41 to 50 of about 586,330 (289)

Loss of histone macroH2A1 in hepatocellular carcinoma cells promotes paracrine-mediated chemoresistance and CD4+CD25+FoxP3+ regulatory T cells activation [PDF]

, 2020
Rationale: Loss of histone macroH2A1 induces appearance of cancer stem cells (CSCs)-like cells in hepatocellular carcinoma (HCC). How CSCs interact with the tumor microenvironment and the adaptive immune system is unclear. Methods: We screened aggressive
Drovakova A., Giallongo S., Li Volti G., Lo Re O., Mazza T., Rappa F., Roskams T., Sanna P., Tsochatzis E., Van Haele M., Vinciguerra M., Vinh Luong T.   +11 more
core   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

METTL21A promotes hepatocellular carcinoma progression via methylating and stabilizing BAG3

npj Precision Oncology
Protein methyltransferases regulate diverse physiological and pathological processes through histone and non-histone substrate methylation. While the role of histone methyltransferases in tumorigenesis is well-established, the contribution of non-histone
Ping Zhan, Yizhe Cheng, Yingcan Wu, Jing Lu, Jing Wen, Xiaoqin Chi, Changhong Luo, Yiwei Peng, Xijun Chen, Fuqiang Wang, Zhenyu Yin, Chengrong Xie   +11 more
doaj   +1 more source

MLN2238 exerts its anti-tumor effects via regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma

Frontiers in Pharmacology, 2022
Background: Intrahepatic Cholangiocarcinoma (iCCA) is a highly malignant tumor with limited treatment options that contributes largely to cancer-related deaths worldwide.
Hao Xu, Hao Xu, Hao Xu, Hao Xu, Hao Xu, Hao Xu, Guangyu Xu, Guangyu Xu, Guangyu Xu, Guangyu Xu, Guangyu Xu, Guangyu Xu, Qianhui Xu, Qianhui Xu, Qianhui Xu, Qianhui Xu, Qianhui Xu, Qianhui Xu, Chang Xu, Chang Xu, Chang Xu, Chang Xu, Chang Xu, Chang Xu, Xiaohu Zhou, Yang Bai, Yang Bai, Yang Bai, Yang Bai, Yang Bai, Yang Bai, Lu Yin, Yuan Ding, Yuan Ding, Yuan Ding, Yuan Ding, Yuan Ding, Yuan Ding, Weilin Wang, Weilin Wang, Weilin Wang, Weilin Wang, Weilin Wang, Weilin Wang   +43 more
doaj   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Hepatocellular Carcinoma [PDF]

Cold Spring Harbor Perspectives in Medicine, 2015
The hepatitis B virus (HBV) is a widespread human pathogen that causes liver inflammation, cirrhosis, and hepatocellular carcinoma (HCC). Recent sequencing technologies have refined our knowledge of the genomic landscape and pathogenesis of HCC, but the mechanisms by which HBV exerts its oncogenic role remain controversial.
Marie-Annick, Buendia, Christine, Neuveut   +1 more
openaire   +2 more sources

Hepatocarcinoma with tumor thrombus occupying the right atrium and portal vein in a patient with hereditary hemochromatosis and liver cirrhosis [PDF]

, 2018
We present the case of a 46-year old patient with Child-Pugh class C cirrhosis with MEDL-Score 16, and hepatocellular carcinoma invading the inferior vena cava and the right atrium.
Breaban, Iulia, Cozma, Angela, Fabian, Ovidiu, Mihailov, Anca, Muresan, Flaviu, Negrean, Vasile, Orasan, Olga Hilda, Sampelean, Dorel, Secara, Sorina Cezara, Stefan, Andreea Maria, Tarmure Sarlea, Simina, Urian, Laura   +11 more
core   +1 more source

Impact of remnant vital tissue after locoregional treatment and liver transplant in hepatocellular cancer patients. A multicentre cohort study [PDF]

, 2018
The role of pathological findings after locoregional treatments as predictors of hepatocellular cancer recurrence after liver transplantation has been poorly addressed.
Angelico, Mario, Angelico, Roberta, Carvalheiro, Amanda, Iesari, Samuele, Komuta, Mina, Lai, Quirino, Lerut, Jan, Manzia, Tommaso M., Montalti, Roberto, Nicolini, Daniele, Orlacchio, Antonio, Palmieri, Giampiero, Perera, M. Thamara P. R., Quaranta, Claudia, Scarpelli, Marina, Shah, Tahir, Tisone, Giuseppe, Vivarelli, Marco   +17 more
core   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

ONC206 targeting ClpP induces mitochondrial dysfunction and protective autophagy in hepatocellular carcinoma cells

Neoplasia: An International Journal for Oncology Research
Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for approximately 90 % of all cases. ONC201, a member of the imipridone drug family, has shown promising therapeutic potential and a good safety profile in both malignant ...
Jiahao Cao, Fei Cao, Chuanzheng Wang, Zhen Jiao, Yuting You, Xiaomin Wang, Wenxiu Zhao   +6 more
doaj   +1 more source